Biomarker Card
This biomarker card gives comprehensive information about each biomarker.
| Detailed Information | |
|---|---|
| Biomarker ID | 1891 |
| PMID | 30641210 |
| Year | 2019 |
| Biomarker | Interleukin 8 [SNP: rs4073 AA vs. TA+TT] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | Downregulated in PCa: [4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; ] Upregulated in PCa: [1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone] |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.58 (95% CI: 0.35–0.96) |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign Prostatic hyperplasia |
| Type of Biomarker | Diagnostic/Prognostic |
| Cohort | 530 individuals including 130 PCa patients, 200 BPH patients and 200 male controls were selected for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.03 |
| Method Used | ARMS-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |